Edonia raises €15 million to expand microalgae ingredients
The France-based FoodTech company says the funding will support wider commercial use of its ready-to-eat protein ingredients, with more than €30 million in pre-contracted revenue already secured.
Edonia has raised €15 million to expand commercial use of microalgae-based protein ingredients, according to EU-Startups. The France-based FoodTech company makes ready-to-eat products for food manufacturers and foodservice operators. It says more than €30 million in pre-contracted revenue has already been secured from industrial partners.
The funding is led by SWEN Blue Ocean 2, Asterion Ventures, EIT Food and Bpifrance. The available account does not identify a regulator, legal process or regulatory decision connected with the investment. Edonia’s response is represented by CEO Hugo Valentin’s public statement about the company’s intended next stage.
Funding targets broader commercial use
Edonia says the capital will help bring its microalgae-based ingredients into broader commercial use. Its customers include food manufacturers and foodservice operators, placing the company between ingredient production and prepared food applications. The account describes current use in catering and ready-meal products. It does not specify how much funding is assigned to manufacturing, sales or any particular product.
The company’s stated commercial position includes more than €30 million in pre-contracted revenue from industrial partners. That figure is presented as contracted future revenue, rather than as sales already recognised. The source does not provide the contracts’ duration, delivery timetable or individual counterparties. Those details limit what can be concluded about when the revenue will be realised.
A patented process shapes the product
Edonia was founded in 2023 and develops ready-to-eat protein ingredients made from microalgae. Its process, Edonization, transforms spirulina into a whole-food protein ingredient. The method was developed with AgroParisTech Innovation, and the source describes it as patented. In plain terms, the process is designed to turn the microalgae into an ingredient suitable for food preparation.
The first product, Edo, is made by cooking spirulina in oil at a controlled temperature. Edonia says the result has a tender texture intended to address spirulina’s distinctive taste, which the company identifies as a barrier to wider adoption. The product contains 27g of protein per 100g and is also described as rich in iron. The source gives no independent testing details for those product characteristics.
Investors back a commercial pipeline
The round was led by SWEN Blue Ocean 2, Asterion Ventures, EIT Food and Bpifrance. Asterion Ventures Partner Reygrobellet said the product was developed to address taste, natural ingredients, industrial scalability and market positioning. The investment account also reports that Edonia built a commercial pipeline before its factory was operating. That assessment is attributed to the investor, rather than presented as an independent finding.
CEO Hugo Valentin said the company’s goal is to produce enough ingredient and supply food manufacturers and foodservice operators across Europe, Japan and the US. The statement describes an ambition and does not set out production volumes or delivery dates. The source gives no factory capacity, production schedule or breakdown of planned geographic sales. The funding’s precise allocation also remains undisclosed in the supplied account.
Production plans remain unspecified
The reported funding and contracted revenue indicate that Edonia is moving from product development towards commercial supply. However, the material does not state when expanded production will begin or how quickly customers will receive the ingredient. It also does not give the size or terms of the round beyond the announced amount and lead investors. No regulatory authority or legal status is identified in the account.
The next verifiable steps would be further company information on production, deliveries and the timing of commercial expansion. Any assessment of execution will depend on those details becoming public. For now, the stated pipeline and the company’s production ambition frame the commercial case presented for the raise.